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anti–tumor necrosis factor therapies in the
United States Corrona registry
Leslie R. Harrold1*, George W. Reed2, Robert Magner1, Ashwini Shewade3, Ani John3, Jeffrey D. Greenberg2,4
and Joel M. Kremer5
Abstract
Introduction: Patients with active rheumatoid arthritis (RA) despite anti–tumor necrosis factor(anti-TNF)agent
treatment can switch to either a subsequent anti-TNF agent or a biologic with an alternative mechanism of action,
such as rituximab; however, there are limited data available to help physicians decide between these 2 strategies.
The objective of this analysis was to examine the effectiveness and safety of rituximab versus a subsequent anti-TNF
agent in anti-TNF–experienced patients with RA using clinical practice data from the Corrona registry.
Methods: Rituximab-naive patients from the Corrona registry with prior exposure to ≥1 anti-TNF agent who
initiated rituximab or anti-TNF agents (2/28/2006-10/31/2012) were included. Two cohorts were analyzed: the
trimmed population (excluding patients who fell outside the propensity score distribution overlap) and the stratified-
matched population (stratified by 1 vs≥2 anti-TNF agents, then matched based on propensity score). The primary
effectiveness outcome was achievement of low disease activity (LDA)/remission (Clinical Disease Activity Index≤10) at
1 year. Secondary outcomes included achievement of modified American College of Rheumatology (mACR) 20/50/70
responses and meaningful improvement (≥0.25) in modified Health Assessment Questionnaire (mHAQ) score at 1 year.
New cardiovascular, infectious and cancer events were reported.
Results: Estimates for LDA/remission, mACR response and mHAQ improvement were consistently better for rituximab
than for anti-TNF agent users in adjusted analyses. The odds ratio for likelihood of LDA/remission in rituximab versus
anti-TNF patients was 1.35 (95 % CI, 0.95-1.91) in the trimmed population and 1.54 (95 % CI, 1.01-2.35) in the stratified-
matched population. Rituximab patients were significantly more likely than anti-TNF patients to achieve mACR20/50 and
mHAQ improvement in the trimmed population and mACR20 and mHAQ in the stratified-matched population. The rate
of new adverse events per 100 patient-years was similar between groups.
Conclusions: In anti-TNF–experienced patients with RA, rituximab was associated with an increased likelihood of
achieving LDA/remission, mACR response and physical function improvement, with a comparable safety profile, versus
subsequent anti-TNF agent users.
Trial registration: ClinicalTrials.gov NCT01402661. Registered 25 July 2011.
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Introduction
Rheumatoid arthritis (RA) is a chronic, debilitating disease
characterized by persistent synovitis and systemic inflam-
mation. When untreated or uncontrolled, RA can cause
significant pain, functional disability and decreased quality
of life, and increased risk of death [1]. Nonbiologic
disease-modifying antirheumatic drugs (nbDMARDs),
such as methotrexate (MTX), are the mainstay of therapy
and the first class of agents to be used. In patients with ac-
tive RA despite nbDMARD therapy, treatment guidelines
recommend either step-up to combination DMARD ther-
apy or initiation of a biologic agent.
The first choice of biologic therapy is typically an anti-
tumor necrosis factor(anti–TNF) agent [2]. While anti-
TNF agents have been shown in large randomized con-
trolled trials (RCTs) to be effective at improving the signs
and symptoms of RA, and preventing damage as identified
on radiography, between 30 and 40 % of patients in
clinical trials and real-world practice settings develop an
inadequate response to anti-TNF agents, either due to a
primary lack of response or secondary treatment failure
due to drug resistance or intolerance [3–6]. Patients with
active disease despite anti-TNF therapy can subsequently
switch to either a different anti-TNF agent or a biologic
agent with an alternative mechanism of action (MOA),
such as rituximab. Currently, limited data are available to
physicians trying to decide between these two strategies.
Rituximab, a chimeric monoclonal antibody that de-
pletes CD20+ B cells, in combination with MTX has
demonstrated sustained efficacy and a well-characterized,
long-term safety profile in patients with RA who have had
an inadequate response to anti-TNF agents [7, 8]. The
dose for rituximab in combination with MTX is 2 ×
1000 mg administered by intravenous infusions separated
by 2 weeks (one course) every 24 weeks or based on clin-
ical evaluation, but not sooner than every 16 weeks. The
addition of rituximab and other non-anti-TNF agents to
the anti-RA armamentarium has increased the treatment
options available to patients who have failed to respond to
previous anti-TNF therapy. Although there have been no
RCTs directly comparing the effectiveness of rituximab
with that of a subsequent anti-TNF agent in these
patients, this issue has been studied in routine clinical
practice in a few observational trials from Europe [9–14];
however, comparative effectiveness data are limited for the
use of rituximab in patients in the USA. As previously
reported, certain clinical characteristics (e.g., disease
duration, autoantibody seropositivity, comorbidities and
smoking prevalence) and treatment patterns, including
dosing of biologic agents and use of prednisone, can vary
widely between patients in the USA compared with Euro-
pean registries, which may impact study results [15, 16]. In
addition, access to biologic agents may differ from country
to country based on payer or regulatory restrictions,
further highlighting the need for USA-specific data. The
objective of this analysis was to evaluate the effectiveness
and safety of rituximab compared with that of a subse-
quent anti-TNF agent in patients with RA who had prior
anti-TNF exposure, using clinical practice data from the
Corrona registry.
Methods
Data source
The Corrona registry is an independent, prospective, ob-
servational cohort of patients with RA, who were
recruited at >160 private and academic practice sites
across 40 states in the USA; additional details have been
published previously [17]. Data on approximately 39,950
patients with RA have been collected as of 31 March
2014. The Corrona database includes information about
285,726 patient visits and approximately 119,298 patient-
years of follow up observation time, with a mean time of
patient follow up of 3.6 years (median 2.8 years). For this
national study, approvals for data collection and analyses
were obtained from a central institutional review board
(New England Institutional Review Board) for private
practice sites participating within Corrona. For the <20 %
of sites that are affiliated with an academic medical center,
the local institutional review board was the Institutional
Review Board of record.
Study population
Data were collected from patients with RA from the
Corrona registry who initiated rituximab or a subse-
quent anti-TNF agent (adalimumab, etanercept, golimu-
mab, infliximab, certolizumab) on or after 28 February
2006. The study population was limited to patients who
had received ≥1 anti-TNF agent and had not previously
received rituximab. Patients must have had the following
data available to be included in the study: date of the
first rituximab infusion or initiation of a subsequent
anti-TNF agent; follow-up visit at 1 year (±3 months); ≥1
visit between baseline and 1-year follow up; and Clinical
Disease Activity Index (CDAI) measurements at baseline
and 1-year follow up. For patients whose anti-TNF initi-
ation occurred between visits, a prior visit (within
4 months of initiation) was used. Patients with CDAI
low disease activity (LDA) or remission at initiation, or
with a diagnosis of lymphoma prior to initiation, were
excluded from the study (Fig. 1). All patients provided
written informed consent prior to participation.
Measures and data collection
Data from Corrona were collected during the study period
(28 February 2006 to 31 October 2012) from physician
and patient questionnaires completed during routine clin-
ical encounters. Data on use of nbDMARDs and biologic
DMARDs, 28-joint tender and swollen joint counts,
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physician and patient global assessments of disease activ-
ity, patient assessment of pain and modified Health As-
sessment Questionnaire (mHAQ) scores assessing
physical function were recorded at the time of the clinical
encounter [18]. Data on demographics, insurance status,
comorbid conditions, RA disease characteristics and RA
medications were available for ≥99 % of patients.
Drug exposure cohorts
To balance for predisposing factors that may increase a
patient’s likelihood of receiving either rituximab or an
anti-TNF agent, a propensity score - or the probability
of treatment selection - was calculated for each eligible
patient using baseline (at the time of drug initiation)
patient demographics (age, sex, race and insurance type),
disease characteristics (rheumatoid factor (RF) seroposi-
tivity, duration of RA, American Rheumatism Associ-
ation functional class, tender and swollen joint counts,
patient and provider global assessments, patient pain
and functional status), comorbidities (cardiovascular dis-
ease, cancer and/or diabetes mellitus), past medication
history (number of prior nbDMARDs, anti-TNF agents
and/or non–anti-TNF agents) and concurrent medica-
tions (prednisone and/or MTX). The rationale for the
methodology for this approach is provided in the supple-
mentary materials (see Additional file 1). For the first
cohort (trimmed population), patients who fell outside
the overlap of the propensity score distributions were
excluded (see Additional file 2: Figure S1). The second co-
hort (stratified-matched population) included rituximab-
treated and anti-TNF-agent–treated patients who were
stratified by prior treatment with one versus two or more
anti-TNF agents, and then matched within each stratum
based on propensity score estimated within each strata
without replacement, using calipers of 0.01. The resulting
stratified-matched population resulted in greater similarity
between the two drug exposure groups.
Study outcomes
The primary outcome was the proportion of patients in
each group who achieved CDAI LDA or remission
(CDAI score ≤10) at 1 year [18]. Secondary outcomes in-
cluded the proportion of patients who achieved modified
American College of Rheumatology (mACR) 20/50/70
responses, which omit the acute-phase reactant labora-
tory components, and the proportion who achieved a
clinically meaningful improvement in functional status,
defined as a decrease of ≥0.25 from baseline in the
mHAQ score, at 1 year [19–21].
Safety events reported by providers over the 12-month
study were examined and included infections (all infec-
tions and serious infections), cardiovascular events and
new malignancies. Infections identified in this analysis
included cellulitis, sinusitis, diverticulitis, sepsis, pneumo-
nia, bronchitis, gastroenteritis, meningitis, encephalitis,
urinary tract infection, upper respiratory tract infection,
Fig. 1 Patient disposition. 1Propensity scores were calculated using baseline patient demographic data, disease characteristics (severity, duration and
activity), comorbidities, past medication history and concurrent medications. Anti-TNF anti–tumor necrosis factor agent, CDAI Clinical Disease Activity Index
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tuberculosis, joint infection, bursal infection and all other
hospitalized and ambulatory infections. Cardiovascular
events included cardiac arrest, congestive heart failure,
myocardial infarction, coronary artery disease, unstable
angina, ventricular arrhythmia, cardiac revascularization
stroke, transient ischemic attack and deep vein throm-
bosis. Cancer events included breast cancer, lung cancer,
lymphoma, skin cancer (not specified, squamous cell and
melanoma) and other cancer diagnoses.
Analysis and statistical methods
Patients were included regardless of retreatment with ri-
tuximab or persistence with anti-TNF therapy. Baseline
patient demographics and clinical and disease character-
istics were compared between the two drug-exposure
cohorts, and standardized differences were estimated.
Response was defined as achievement of primary and
secondary outcomes at 1 year regardless of continuation
of initial treatment. Nonresponse was imputed for pa-
tients who switched biologic agents. Descriptive statistics
were used to examine rates of response at 1 year overall
and by treatment pattern subgroup: (1) patients who
remained on the drug, (2) those who were not retreated
with rituximab or who discontinued anti-TNF therapy
and did not initiate another biologic agent, and (3) those
who switched to another biologic agent.
Multivariable logistic regression models were fit to
estimate odds ratios (ORs) and 95 % CIs comparing re-
sponse rates in rituximab users to anti-TNF agent users
in the two populations. Covariates used in the multivari-
able logistic regression models of the trimmed popula-
tion included baseline parameters with a standardized
difference of >0.1 and four factors chosen a priori to
ensure no residual confounding despite the propensity
score methodology: baseline CDAI score, steroid use
(current or not), number of anti-TNF agents previously
used (1 vs ≥2) and concomitant MTX use. The resulting
multivariable logistic regression models were adjusted
for fixed and random effects. Both patient and provider
random effects were examined; however, only patient-
related random effects were included in the model be-
cause provider random effects did not have a significant
impact on responses. In the stratified-matched popula-
tion, all baseline characteristics had standardized differ-
ences <0.1 except for baseline CDAI score (standardized
difference 0.14). Therefore, logistic regression models
were fit to estimate ORs and 95 % CIs comparing
response with rituximab to that with anti-TNF agents,
including baseline CDAI score as a covariate in the
model and random effect for matched pairs (i.e., patients
clustered within matched pairs).
Of the patients with available data on RF status, RF
seropositivity was reported in 82 % (141 of 173) and
72 % (315 of 435) of patients receiving rituximab and
anti-TNF agents, respectively. Of note, a missing indicator
was used when RF was included as a variable in the multi-
variate model as well as the propensity score model. Inclu-
sion of RF status as a covariate resulted in <5 % variation
in OR estimates. Due to the impact on power of limiting
the study sample to only those for whom serologic data
were available, the ORs reported do not include this
covariate. Additionally, no significant differences were
observed in prednisone and nbDMARD use between users
of rituximab or anti-TNF agents overall, or between sub-
groups in the stratified-matched population. Because no
significant differences were found, we chose not to include
these factors in the trimmed population (because any dif-
ference would likely be controlled for in the multivariable
model) and stratified-matched analyses.
Safety event rates were calculated based on the
number of events reported by providers, divided by the
duration of exposure. In the trimmed population, sex-
and age-standardized adverse event (AE) rates among ri-
tuximab users were calculated based on the age and sex
distribution in the users of anti-TNF agents. Safety events
were also compared in the stratified-matched population.
The ratio of rates for the rituximab users in relation to the
users of anti-TNF agents was generated for both the
trimmed and stratified-matched populations.
Results
Baseline demographics
A total of 265 rituximab users and 739 users of subse-
quent anti-TNF agents met the inclusion criteria prior to
implementation of the propensity scores (Fig. 1). Two
patients receiving anti-TNF (one with low and one with
high propensity scores) were excluded from the trimmed
population, leaving patients on 265 rituximab and 737
on anti-TNF agents for analysis. Approximately 16.2 %
of rituximab users and 29.4 % of users of anti-TNF
agents switched to another biologic agent. Among rituxi-
mab users, 21.5 % were not retreated compared with
19.1 % of patients on anti-TNF agents who discontinued
their drug without initiating a new biologic agent. The
stratified-matched population included 205 patients each
in the rituximab and anti-TNF groups. Of the users of
rituximab and anti-TNF agents, 15.1 % and 34.6 %, re-
spectively, switched to a new biologic agent. The propor-
tion of patients who were not retreated with rituximab
was 22.9 %. The proportion of patients on anti-TNF
agents who discontinued the anti-TNF treatment but did
not initiate another biologic agent was 19.5 %.
Baseline characteristics of patients in the trimmed and
stratified-matched populations are presented in Table 1.
In the trimmed population, rituximab users had a longer
duration of disease, worse disease activity scores and
prior exposure to a greater number of nbDMARDs and
biologic agents than users of anti-TNF agents.
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Rates of LDA or remission at 1 year
Overall rates of LDA or remission at 1 year and by sub-
group (those who remained on drug, those who stopped
treatment or those who switched) in both the trimmed
and stratified-matched populations are presented in
Table 2. In the trimmed population, 34.3 % of patients
(91 of 265) receiving rituximab achieved LDA or remis-
sion at 1 year versus 33.7 % of patients (248 of 737)
receiving an anti-TNF agent (P = 0.82). In the stratified-
matched population, the unadjusted rates of LDA or
remission in the rituximab and anti-TNF groups were
36.6 % (75 of 205) and 28.8 % (59 of 205), respectively
(P = 0.09).
In the adjusted logistic regression models, no signifi-
cant differences were found in the likelihood of
achieving LDA or remission between patients in the
trimmed population treated with rituximab and those
treated with anti-TNF agents (Fig. 2; OR, 1.35; 95 %
CI, 0.95, 1.91). In the stratified-matched population,
patients who received rituximab were significantly
more likely to achieve LDA or remission (OR, 1.54;
95 % CI, 1.00, 2.36).
Table 1 Baseline demographics and disease characteristics among patients receiving rituximab or anti-TNF agents, and standardized
differences
Trimmed population Stratified-matched population
Rituximab
(n = 265)
Anti-TNF
(n = 737)
Standardized difference Rituximab
(n = 205)
Anti-TNF
(n = 205)
Standardized difference
Demographics
White, % 87.6 83.5 0.114 84.4 87.3 0.084
Female, % 81.1 79.2 0.049 82.9 81.0 0.051
Age, mean (SD), years 57.8 (11.7) 56.1 (12.4) 0.139 57.6 (11.7) 58.0 (11.5) 0.037
Insurance
Medicare, % 37.7 29.4 0.176 33.7 39.0 0.111
Medicaid, % 7.2 6.4 0.032 7.3 6.3 0.039
Private insurance, % 76.6 78.7 0.050 76.1 74.6 0.034
No insurance, % 1.1 2.3 0.090 1.5 1.5 0.000
History of comorbidities
Cardiovascular disease, % 11.3 7.3 0.137 9.8 11.7 0.063
Cancer, % 9.4 7.7 0.061 10.2 8.8 0.050
Diabetes, % 9.8 10.7 0.030 10.2 10.7 0.016
Clinical characteristics
Disease duration, mean (SD), years 15.4 (10.2) 11.4 (9.4) 0.408 14.6 (10.3) 15.1 (10.5) 0.047
Tender joint count, mean (SD) 9.6 (7.3) 8.7 (7.3) 0.117 9.5 (7.2) 9.1 (7.8) 0.058
Swollen joint count, mean (SD) 8.0 (5.6) 7.5 (5.7) 0.097 7.9 (5.5) 7.4 (5.8) 0.086
Patient global assessment, mean (SD) 54.3 (23.6) 50.6 (25.0) 0.154 53.2 (23.4) 52.7 (25.5) 0.023
Physician global assessment, mean (SD) 42.7 (20.2) 39.3 (20.1) 0.169 42.3 (19.7) 39.8 (19.1) 0.130
Patient pain, mean (SD) 56.5 (24.5) 53.2 (25.5) 0.132 55.3 (24.8) 53.0 (26.2) 0.093
Disability index (mHAQ), mean (SD) 0.78 (0.5) 0.64 (0.5) 0.270 0.74 (0.5) 0.72 (0.5) 0.040
Clinical Disease Activity Index, mean (SD) 27.3 (12.5) 25.2 (11.9) 0.172 27.0 (12.0) 25.7 (12.3) 0.100
Prior medication use
Prior nbDMARDs, n, mean 1.6 1.1 0.396 1.4 1.4 0.031
Prior use of ≥2 anti-TNF agents, % 63.0 26.6 0.786 54.6 54.6 0.000
Prior use of non–anti-TNF biologic agents, % 40.8 13.0 0.657 31.7 33.2 0.031
Concomitant medications
Prednisone, % 43.8 29.3 0.303 39.0 38.5 0.010
Methotrexate, % 57.7 55.9 0.037 57.1 51.7 0.108
Non-methotrexate nbDMARD, % 29.1 24.8 0.095 29.8 30.2 0.011
Anti-TNF Anti–tumor necrosis factor, mHAQ modified Health Assessment Questionnaire, nbDMARD nonbiologic disease-modifying antirheumatic drug
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Rates of secondary outcome measures at 1 year
Unadjusted rates of secondary outcome measures for the
two treatment groups are presented in Table 3. In the
trimmed population, a greater proportion of patients
receiving rituximab achieved greater mACR20/50/70 re-
sponses at 1 year than those who received a subsequent
anti-TNF agent (mACR20, 36.6 % vs 28.7 %; mACR50,
21.1 % vs 17.4 %; mACR70, 10.2 % vs 8.8 %), although
the mACR50 and mACR70 comparisons were not sig-
nificant. Similarly, a greater proportion of rituximab
users achieved a clinically meaningful improvement in
mHAQ score at 1 year compared with users of anti-TNF
agents (33.2 % vs 24.2 %). In the stratified-matched
population, rates of mACR20 (38.1 % vs 22.0 %),
mACR50 (21.0 % vs 13.7 %) and mACR70 responses
(10.2 % vs 7.3 %) and mHAQ score improvement
(34.2 % vs 23.9 %) were generally consistent with
respective rates observed in the trimmed population;
crude differences between rituximab users and their
stratified-matched anti-TNF counterparts were of greater
magnitude.
In a multivariate analysis of the trimmed population,
patients who received rituximab were significantly more
likely than those who received a subsequent anti-TNF
agent to achieve mACR20 (Fig. 2; OR 1.66; 95 % CI 1.17,
2.36), mACR50 (OR 1.53; 95 % CI 1.01, 2.30) and
mHAQ score improvement (OR 1.46; 95 % CI 1.01,
2.12) but were not significantly more likely to achieve
Table 2 Unadjusted response rates for LDA or remission at 1 year in all patients and by subgroup in the trimmed and stratified-
matched populations
Trimmed population Stratified-matched population
Rituximab Anti-TNF agent Rituximab Anti-TNF
(n = 265) (n = 737) (n = 205) (n = 205)
Patients,
number
LDA or
remission
Patients,
number
LDA or
remission
Patients,
number
LDA or
remission
Patients,
number
LDA or
remission
Overall, n (%)* 265 91 (34.3) 737 248 (33.7) 205 75 (36.6) 205 59 (28.8)
Remained on drug 165 71 (43.0) 379 196 (51.7) 127 59 (46.5) 94 45 (47.9)
Not retreated with rituximab or
discontinued anti-TNF
57 20 (35.1) 141 52 (36.9) 47 16 (34.0) 40 14 (35.0)
Switched 43 N/A 217 N/A 31 N/A 71 N/A
*P = 0.82 for the trimmed population; P = 0.09 for the stratified-matched population. Anti-TNF anti–tumor necrosis factor, LDA low disease activity, N/A not available
Fig. 2 Adjusted odds ratio (OR) for effectiveness outcomes in the trimmed and stratified-matched populations. 1Adjusted for baseline demographics,
disease activity, comorbidity and medication use (past and current). 2Patients with missing covariate information (n = 14) were excluded. 3Adjusted for
disease activity. Anti-TNF anti–tumor necrosis factor, LDA low disease activity, mACR modified American College of Rheumatology criteria, mHAQ modi-
fied Health Assessment Questionnaire
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mACR70 (OR 1.59; 95 % CI 0.92, 2.76). In the stratified-
matched population, rituximab users were more likely to
achieve mACR20 (OR 2.15; 95 % CI 1.35, 3.42) and clin-
ically meaningful improvement in mHAQ score (OR
1.66; 95 % CI 1.07, 2.59) than those who received a sub-
sequent anti-TNF agent (Fig. 2). No significant differ-
ences were found between the treatment groups in the
likelihood of achieving mACR50 (OR 1.64; 95 % CI 0.95,
2.85) or mACR70 (OR 1.38; 95 % CI 0.68, 2.83). For
both the primary and secondary outcomes, type of
therapy (defined as monotherapy, combination therapy
with MTX and combination therapy with a non-MTX
DMARD) was not a moderating factor.
Safety
The rates of AEs in the two populations are reported in
Table 4. The standardized rates per 100 person-years for
cancer, infection and cardiovascular events in patients
on rituximab versus anti-TNF agents were 1.5 versus 1.9,
37.7 versus 41.0 and 1.8 versus 1.4, respectively. No sig-
nificant differences were observed between the two
groups. Similar rates were reported in the stratified-
matched population. More detailed information on the
number and type of events and available patient-years is
summarized in Additional file 3: Table S1.
Discussion
While anti-TNF agents are the most widely used biologic
drugs in RA, not all patients respond adequately, and
limited data are available to rheumatologists to rationally
determine subsequent therapy in anti-TNF–experienced
patients. Due to the scarcity of head-to-head RCTs,
several observational studies have been conducted to
analyze this important clinical question. This is the first
observational study in a USA population to assess the
comparative effectiveness of rituximab versus that of an
anti-TNF agent among anti-TNF-experienced patients
with moderate-to-severe disease. In this study, patients
from real-world US rheumatology practices were en-
rolled. To minimize selection bias, we identified the drug
exposure cohorts by propensity score, excluding those
who fell outside the area of common support (trimmed
population) and propensity score–matched patients
stratified by number of prior anti-TNF agents (stratified-
matched population). In adjusted analyses of two drug-
exposure cohorts categorized using propensity scores,
patients treated with rituximab were 35 to 50 % more
likely to achieve LDA or remission than those treated
with a subsequent anti-TNF agent, although this was not
statistically significant in the trimmed population.
Patients treated with rituximab were also more likely to
achieve mACR20 and mACR50 responses (trimmed
population only) and demonstrate clinically meaningful
improvement in mHAQ scores than those treated with a
subsequent anti-TNF agent. We also found similar drug-
related safety in the two treatment groups - comparable
to published reports [15] - which is essential information
for providers when deciding the next therapeutic step.
The results of this study reinforce the important
observations from European studies that switching to ri-
tuximab is superior to receiving another anti-TNF agent,
and expand upon these findings with a rigorous evaluation
of the comparative safety of these two drug classes, con-
sistent with the Institute of Medicine definition of com-
parative effectiveness [22]. This is important because
patients and the rheumatologists treating them need a
Table 3 Unadjusted rates of mACR20/50/70 and mHAQ
improvement
Outcome,
%
Trimmed population Stratified-matched population
Rituximab Anti-TNF P
value
Rituximab Anti-TNF P
value(n = 265) (n = 737) (n = 205) (n = 205)
mACR20 36.6 28.7 0.02 38.1 22.0 0.001
mACR50 21.1 17.4 0.17 21.0 13.7 0.005
mACR70 10.2 8.8 0.46 10.2 7.3 0.29
mHAQ 33.2 24.2 0.004 34.2 23.9 0.02
Anti-TNF anti–tumor necrosis factor, mACR modified American College of
Rheumatology criteria, mHAQ modified Health Assessment Questionnaire
Table 4 Rates of adverse events
Events/100 PY
(95 % CI)
Trimmed populationa Stratified-matched population
Rituximab Anti-TNF Ratio of Rituximab Anti-TNF Ratio of
ratesb(n = 265) (n = 737) ratesb (n = 205) (n = 205)
Cancer 1.5 (0.0, 3.0) 1.9 (0.8, 3.0) 0.8 (0.3, 2.3) 1.6 (0.5, 4.9) 2.9 (1.2, 7.0) 0.5 (0.1, 2.8)
Infection
All events 37.7 (29.9, 45.5) 41.0 (36.0, 46.0) 0.9 (0.7, 1.2) 38.1 (30.2, 48.0) 44.4 (35.4, 55.5) 0.9 (0.6, 1.2)
Serious infections 1.2 (0.0, 2.7) 2.8 (1.3, 4.3) 0.4 (0.1, 1.3) 2.0 (0.7, 6.3) 4.5 (2.0, 10.0) 0.5 (0.1, 2.1)
Cardiovascular 1.8 (0.2, 3.4) 1.4 (0.5, 2.4) 1.3 (0.4, 4.0) 1.6 (0.5, 4.9) 2.9 (1.2, 7.0) 0.5 (0.1, 2.8)
aRates in the trimmed population were standardized by age and sex. Confidence intervals were calculated using a Poisson approximation of the standard error.
bRatio of rituximab/anti-TNF agent rates. Anti-TNF anti–tumor necrosis factor, PY patient-years
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comprehensive evaluation of the benefit − risk profiles of
different biologic agents to optimize decision-making. In a
Swiss cohort study, rituximab versus an alternative anti-
TNF agent was associated with a greater improvement in
disease activity over 6 months of treatment, regardless of
the number of previous anti-TNF agent exposures [9]. In a
Dutch cohort study, patients who previously failed to
respond to two anti-TNF agents demonstrated greater im-
provement in disease activity at 1 year after treatment with
rituximab versus treatment with a third anti-TNF agent
[12]. In the Spanish MIRAR study, switching to rituximab
versus subsequent adalimumab or infliximab significantly
improved disease activity [11]. No additional benefit was
demonstrated when rituximab was compared with pooled
anti-TNF agents, suggesting that the difference in response
was based on the specific anti-TNF agent used [11]. In a
previous Corrona study, rates of response and remission
with a subsequent anti-TNF agent did not differ by mech-
anism of anti-TNF blockade [23]; thus, this stratification
was not performed in the patients on anti-TNF therapy.
Studies of European patients with RA from the British So-
ciety for Rheumatology Biologics Register and from Span-
ish and Dutch cohorts have also found greater
improvement in physical function after switching to rituxi-
mab versus an alternative anti-TNF agent [11, 12, 14].
We believe that the findings of this study have major
clinical relevance for practicing rheumatologists. Given
the growing number of biologic agents indicated for RA,
with their myriad mechanisms of action, comparative data
are especially important for rheumatologists to guide
decision-making to ensure that patients are achieving the
best clinical outcomes. After head-to-head RCTs, observa-
tional studies are the best approach for evaluating com-
parative treatment outcomes. In particular, understanding
treatment response when switching to an agent with an
alternative MOA versus within a drug class is essential
when selecting treatments. This study adds to the body of
knowledge because it compared B-cell depletion to TNF-α
pathway blockade. Prior studies demonstrating similar
effectiveness between a subsequent anti-TNF agent and
abatacept, a selective co-stimulation modulator, in pa-
tients with RA suggests that changing the MOA is not
enough to result in improved outcomes; rather, it is the
specific target of therapy that matters [24].
This study had several strengths. It is the largest known
comparative effectiveness study of rituximab versus anti-
TNF therapy in the USA and included a nationwide sam-
pling of patients with RA. This is important because
patient characteristics have been shown to differ between
American and European registry studies, reinforcing the
need for complementary USA- and Europe-based effect-
iveness data [15]. The all-comers study design recruited
individuals from multiple rheumatology centers, resulting
in a range of patients with real-world disease activity and
comorbidities not often seen in RCTs. In addition to
evaluating both patient- and physician-reported outcome
measures, robust methodology was used. Whereas prior
studies have excluded patients who switched biologic
agents and censored observations after treatment inter-
ruptions, response in this study was evaluated at 1 year in
all patients, regardless of continuation of initial treatment,
and imputed nonresponse for switchers only [10]. This
method has been described previously and was adopted to
generate a more conservative estimate of effectiveness
[25]. It accurately accounts for real-world situations when
a drug may be considered discontinued (e.g., not retreat-
ing with rituximab), despite continuing to be beneficial to
patients. Because retreatment with rituximab was at the
discretion of the provider, the estimates are likely conser-
vative. Additionally, comparative effectiveness was broadly
defined, with evaluation of response, function and safety
between the two drug-exposure cohorts, which had not
been done in the European cohorts. All three elements are
required when communicating with patients. Physicians
need to discuss both the benefits (likelihood of response
and improved patient-reported functional outcomes) and
the risks (AEs) with patients for shared decision-making.
This study also had some limitations related to the
challenges of operationalizing available, real-world data
and applying analytical methods conservatively. There is
always concern that patients enrolled in registries may
not reflect the type of patients observed elsewhere in
general practice; however, this is a general limitation of
all real-world observational studies. A previous study
demonstrated that de-identified data from a subset of
patients in Corrona shared similar demographic and
clinical characteristics with those patients in the USA
Medicare population who filed rheumatology-based
claims, suggesting that data from Corrona may be
generalizable to the RA population in the USA [26]. The
sample size included patients with prior exposure to
between one and three anti-TNF agents. Because previ-
ous studies have shown that patients who have failed to
respond to only one prior biologic agent respond signifi-
cantly better to a new agent than those who have failed
to respond to two or more biologic agents, this may
have introduced bias if the number of prior anti-TNF
agents differed by drug-exposure status [27]. Rituximab
users were matched to patients on anti-TNF agents with
the same number of prior exposures to anti-TNF agents
to address this limitation. However, this did result in a
smaller sample size. Also, as in any observational study,
bias is a concern because physicians prescribe therapies
based on the patient’s profile, and treatment selection is
not random. To overcome this limitation, two cohorts
were analyzed: patients with propensity scores within
the area of common support and those matched by pro-
pensity score and stratified by prior use of anti-TNF
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therapy. Due to sample size considerations, sensitivity
analyses were not performed based on reasons for dis-
continuation of the prior anti-TNF agent, although other
studies have shown that this can influence treatment
response [10]. It is possible that the occurrence of a ser-
ious AE may influence the likelihood of whether a
patient receiving an anti-TNF agent switches to a bio-
logic agent with an alternate MOA, such as rituximab,
or initiates another anti-TNF agent. However, given the
risks associated with rituximab treatment, it was not
expected that there would be differential prescribing
patterns favoring one agent vs another based on AEs
associated with the initial anti-TNF therapy. Similarly,
while a greater proportion of patients on anti-TNF ther-
apy switched biologic therapies compared to rituximab
users, thereby influencing the results, there was no rea-
son to believe that physicians used different criteria for
switching. Outcomes were evaluated over a 12-month
period, allowing both treatment groups ample time to
switch agents if they were not experiencing substantial
improvement based on MOA.
Conclusions
In conclusion, patients who switched to rituximab dem-
onstrated a greater benefit in terms of achieving LDA or
remission, mACR20/50 response and improvement in
physical function, compared with patients who received
a subsequent anti-TNF agent. These results are aligned
with the results seen in clinical trials [28]. Finally, safety
profiles for the two treatment groups were similar and
consistent with what has been previously reported [7].
Taken together, these results suggest that in clinical
practice, rituximab may be more efficacious than a sub-
sequent anti-TNF agent in patients with moderately ac-
tive to severely active RA and prior exposure to anti-
TNF agents. Future analyses are necessary to better
identify which patients are likely to respond to a particu-
lar agent based on their response to prior medications.
Additional files
Additional file 1: Supplementary methods. Covariates included in the
final models in the stratified-matched population, and explanation of the
propensity score methodology and rationale for use of this approach.
(DOCX 34 kb)
Additional file 2: Figure S1. Propensity score distributions for anti-TNF
and rituximab use in patients in the trimmed population who previously
received one anti-TNF agent (a) and those who previously received two
or more anti-TNF agents (b). (PPTX 78 kb)
Additional file 3: Table S1. Rates of adverse events (trimmed population)
in patients receiving rituximab or anti-TNF agents. (DOCX 24 kb)
Abbreviations
AE: adverse event; anti–TNF: anti–tumor necrosis factor; CDAI: Clinical Disease
Activity Index; CI: confidence interval; LDA: low disease activity; mACR
criteria: modified American College of Rheumatology criteria;
mHAQ: modified Health Assessment Questionnaire; MOA: mechanism of
action; MTX: methotrexate; nbDMARD: nonbiologic disease-modifying anti-
rheumatic drug; OR: odds ratio; RA: rheumatoid arthritis; RCT: randomized
controlled trial; RF: rheumatoid factor.
Competing interests
LRH received a research contract from Corrona, LLC; GWR is an employee of
Corrona, LLC; RM is an employee of the University of Massachusetts Medical
School; AS and AJ are employees of Genentech, Inc; JDG is a shareholder
and an employee of Corrona, LLC, and a consultant for AstraZeneca, Celgene,
Novartis and Pfizer; JMK is an employee and shareholder of Corrona, LLC. The
authors do not have any non-financial conflicts of interest to declare.
Authors’ contributions
LRH and GWR had full access to all of the data in the study and take
responsibility for the integrity of the data and the accuracy of the data
analysis. LRH was involved in study design, study management, study
analysis and interpretation, preparing the outline of the first draft of the
manuscript and was responsible for the overall conduct of the study. GWR
was involved in study design, conducting the study, supervision of the
statistical analysis and interpretation and presentation of the results. RM was
involved in study design, study analyses, interpretation of the results and
presentation of the results. AS was involved in the study design, study
analyses, interpretation of the results and presentation of the results. AJ was
involved in the study design, study analyses, interpretation of the results and
presentation of the results. JDG was involved in data collection and data
interpretation. JMK was involved in data collection and data interpretation.
All authors were involved in the drafting, critical review and approval of all
versions of the manuscript, its content and its submission to Arthritis Research &
Therapy and take public responsibility for appropriate portions of the content.
Acknowledgements
This study was sponsored by Corrona, LLC. The Corrona RA registry has been
supported through contracted subscriptions in the last 2 years by AbbVie,
Amgen, AstraZeneca, Genentech, Horizon Pharma, Eli Lilly, Novartis, Pfizer,
Vertex and UCB. Support for third-party writing assistance for this manuscript,
furnished by Vivian Chen, PharmD, and Eric Deutsch, PhD, of Health Interac-
tions, was provided by F. Hoffmann-La Roche, Ltd.
Author details
1Department of Orthopedics, University of Massachusetts Medical School, 55
Lake Ave North, Worcester, MA 01532, USA. 2Corrona, LLC, 352 Turnpike Rd,
Suite 325, Southborough, MA 01772, USA. 3Genentech, Inc, 1 DNA Way,
South San Francisco, CA 94080, USA. 4New York University School of
Medicine, 550 1st Ave, New York, NY 10016, USA. 5Albany Medical Center
and The Center of Rheumatology, 1367 Washington Ave, Suite 101, Albany,
NY 12206, USA.
Received: 25 February 2015 Accepted: 4 September 2015
References
1. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet.
2010;376:1094–108.
2. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012
update of the 2008 American College of Rheumatology recommendations
for the use of disease-modifying antirheumatic drugs and biologic agents in
the treatment of rheumatoid arthritis. Arthr Care Res (Hoboken).
2012;64:625–39.
3. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise
M, et al. Therapeutic effect of the combination of etanercept and
methotrexate compared with each treatment alone in patients with
rheumatoid arthritis: double-blind randomised controlled trial. Lancet.
2004;363:675–81.
4. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al.
Radiographic, clinical, and functional outcomes of treatment with adalimumab
(a human anti-tumor necrosis factor monoclonal antibody) in patients with
active rheumatoid arthritis receiving concomitant methotrexate therapy: a
randomized, placebo-controlled, 52-week trial. Arthritis Rheum.
2004;50:1400–11.
Harrold et al. Arthritis Research & Therapy  (2015) 17:256 Page 9 of 10
5. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR,
et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis.
Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant
Therapy Study Group. N Engl J Med. 2000;343:1594–602.
6. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al.
Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody)
versus placebo in rheumatoid arthritis patients receiving concomitant
methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet.
1999;354:1932–9.
7. van Vollenhoven RF, Emery P, Bingham 3rd CO, Keystone EC, Fleischmann
RM, Furst DE, et al. Long-term safety of rituximab in rheumatoid arthritis:
9.5-year follow-up of the global clinical trial programme with a focus on
adverse events of interest in RA patients. Ann Rheum Dis. 2013;72:1496–502.
8. Keystone EC, Cohen SB, Emery P, Kremer JM, Dougados M, Loveless JE, et al.
Multiple courses of rituximab produce sustained clinical and radiographic
efficacy and safety in patients with rheumatoid arthritis and an inadequate
response to 1 or more tumor necrosis factor inhibitors: 5-year data from the
REFLEX study. J Rheumatol. 2012;39:2238–46.
9. Finckh A, Ciurea A, Brulhart L, Kyburz D, Moller B, Dehler S, et al. B cell
depletion may be more effective than switching to an alternative anti-tumor
necrosis factor agent in rheumatoid arthritis patients with inadequate response
to anti-tumor necrosis factor agents. Arthritis Rheum. 2007;56:1417–23.
10. Finckh A, Ciurea A, Brulhart L, Moller B, Walker UA, Courvoisier D, et al.
Which subgroup of patients with rheumatoid arthritis benefits from
switching to rituximab versus alternative anti-tumour necrosis factor (TNF)
agents after previous failure of an anti-TNF agent? Ann Rheum Dis.
2010;69:387–93.
11. Gomez-Reino JJ, Maneiro JR, Ruiz J, Rosello R, Sanmarti R, Romero AB, et al.
Comparative effectiveness of switching to alternative tumour necrosis factor
(TNF) antagonists versus switching to rituximab in patients with rheumatoid
arthritis who failed previous TNF antagonists: the MIRAR study. Ann Rheum
Dis. 2012;71:1861–4.
12. Blom M, Kievit W, Donders AR, den Broeder AA, Straten VH, Kuper I, et al.
Effectiveness of a third tumor necrosis factor-alpha-blocking agent compared
with rituximab after failure of 2 TNF-blocking agents in rheumatoid arthritis.
J Rheumatol. 2011;38:2355–61.
13. Kekow J, Mueller-Ladner U, Schulze-Koops H. Rituximab is more effective
than second anti-TNF therapy in rheumatoid arthritis patients and previous
TNFalpha blocker failure. Biologics. 2012;6:191–9.
14. Soliman MM, Hyrich KL, Lunt M, Watson KD, Symmons DP, Ashcroft DM, et al.
Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid
arthritis patients who have failed their first anti-tumor necrosis factor therapy?
Comparative analysis from the British Society for Rheumatology Biologics
Register. Arthr Care Res (Hoboken). 2012;64:1108–15.
15. Curtis JR, Jain A, Askling J, Bridges Jr SL, Carmona L, Dixon W, et al. A
comparison of patient characteristics and outcomes in selected European and
U.S. rheumatoid arthritis registries. Semin Arthritis Rheum. 2010;40:2–14.e1.
16. Sandberg ME, Bengtsson C, Kallberg H, Wesley A, Klareskog L, Alfredsson L,
et al. Overweight decreases the chance of achieving good response and
low disease activity in early rheumatoid arthritis. Ann Rheum Dis.
2014;73:2029–33.
17. Kremer JM. The CORRONA database. Clin Exp Rheumatol. 2005;23:S172–7.
18. Anderson J, Caplan L, Yazdany J, Robbins ML, Neogi T, Michaud K, et al.
Rheumatoid arthritis disease activity measures: American College of
Rheumatology recommendations for use in clinical practice. Arthr Care Res
(Hoboken). 2012;64:640–7.
19. Goldman JA, Xia HA, White B, Paulus H. Evaluation of a modified ACR20
scoring system in patients with rheumatoid arthritis receiving treatment
with etanercept. Ann Rheum Dis. 2006;65:1649–52.
20. Greenberg JD, Harrold LR, Bentley MJ, Kremer J, Reed G, Strand V.
Evaluation of composite measures of treatment response without acute-
phase reactants in patients with rheumatoid arthritis. Rheumatology
(Oxford). 2009;48:686–90.
21. Maska L, Anderson J, Michaud K. Measures of functional status and quality
of life in rheumatoid arthritis: Health Assessment Questionnaire Disability
Index (HAQ), Modified Health Assessment Questionnaire (MHAQ),
Multidimensional Health Assessment Questionnaire (MDHAQ), Health
Assessment Questionnaire II (HAQ-II), Improved Health Assessment
Questionnaire (Improved HAQ), and Rheumatoid Arthritis Quality of Life
(RAQoL). Arthr Care Res (Hoboken). 2011;63:S4–13.
22. Iglehart JK. Prioritizing comparative-effectiveness research–IOM
recommendations. N Engl J Med. 2009;361:325–8.
23. Greenberg JD, Reed G, Decktor D, Harrold L, Furst D, Gibofsky A, et al. A
comparative effectiveness study of adalimumab, etanercept and infliximab
in biologically naive and switched rheumatoid arthritis patients: results from
the US CORRONA registry. Ann Rheum Dis. 2012;71:1134–42.
24. Harrold LR, Reed GW, Kremer JM, Curtis JR, Solomon DH, Hochberg MC, et
al. The comparative effectiveness of abatacept versus anti-tumour necrosis
factor switching for rheumatoid arthritis patients previously treated with an
anti-tumour necrosis factor. Ann Rheum Dis. 2015;74:430–6.
25. Harrold L, Reed G, Magner R, Shewade A, John A, Reiss W, et al.
Comparative effectiveness of rituximab versus anti-tumour necrosis factor
switching for rheumatoid arthritis patients. Ann Rheum Dis. 2013;72:460.
26. Curtis JR, Chen L, Bharat A, Delzell E, Greenberg JD, Harrold L, et al. Linkage
of a de-identified United States rheumatoid arthritis registry with
administrative data to facilitate comparative effectiveness research. Arthr
Care Res (Hoboken). 2014;66:1790–8.
27. Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, et al.
Highest clinical effectiveness of rituximab in autoantibody-positive patients
with rheumatoid arthritis and in those for whom no more than one
previous TNF antagonist has failed: pooled data from 10 European
registries. Ann Rheum Dis. 2011;70:1575–80.
28. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al.
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor
therapy: Results of a multicenter, randomized, double-blind, placebo-controlled,
phase III trial evaluating primary efficacy and safety at twenty-four weeks.
Arthritis Rheum. 2006;54:2793–806.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Harrold et al. Arthritis Research & Therapy  (2015) 17:256 Page 10 of 10
